Case report: Dupilumab for the treatment of bullous pemphigoid

Citations Over TimeTop 17% of 2022 papers

Abstract

Bullous pemphigoid (BP) is an inflammatory subepidermal blistering disease with rising prevalence in the elderly individuals. Cytokines associated with Th2-type immune response play an important role in the pathogenesis of BP. The traditional glucocorticoids and immunosuppressants are recommended as first-line drugs, but their therapeutic use is limited by numerous adverse effects. Dupilumab is a humanized monoclonal antibody that targets IL-4 and IL-13. It has recently been approved for the treatment of atopic dermatitis and may be an attractive therapeutic option for BP as well. Herein, we report two cases of BP treated with dupilumab. It was effective and well tolerated. Further research is needed to assess the efficacy of dupilumab in BP patients.

Related Papers

• → Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature(2021)32 cited
• → Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?(2022)30 cited
• → Hydrochlorothiazide vs Venlafaxine: Drug-induced Bullous Pemphigoid(2019)4 cited
• → Pemphigoid in domestic animals(1987)33 cited
• → Localized pemphigoid shares the same target antigen as bullous pemphigoid(1991)18 cited